Healthcare Capital Corp. Announces Adjournment of Special
NEW YORK, NY, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Healthcare Capital Corp. (NASDAQ: HCCC, HCCCW, and HCCCU) (“HCCC”) today announced that on February 18,...
Source: globenewswire.com
📰 Alpha Da News
Page 11 - Alpha Da News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Alpha Da. Real-time updates on events, politics, business and more.
Healthcare Capital Corp. Announces Adjournment of Special
NEW YORK, NY, Feb. 15, 2022 (GLOBE NEWSWIRE) --  Healthcare Capital Corp. (NASDAQ: HCCC, HCCCW, and HCCCU) (“HCCC”) today announced that on February 15,...
Source: globenewswire.com
Alpha Tau Announces New Research Collaboration to Study the Potential of Alpha DaRT to Enhance Immune Stimulation in the Treatment of Breast Cancer
/PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has...
Source: prnewswire.com
Alpha Tau Announces New Research Collaboration to Study the Potential of Alpha DaRT to Enhance Immune Stimulation in the Treatment of Breast Cancer
/PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has...
Source: prnewswire.com
Healthcare Capital Corp Announces Special Meeting Date for
Special Meeting Scheduled for February 15, 2022 The combined company will be named Alpha Tau Medical Ltd. and remain listed on the...
Source: globenewswire.com
Alpha Tau reports positive skin cancer treatment trial
The company said that all 10 patients reached the secondary endpoint for measurement of tumor response to its alpha-radiation cancer therapy.
Israel General Alpha Da Healthcare Capital Corp Alpha Tau Medical Diffusing Alpha Emitters Radiation Therapy Healthcare Capital
Source: globes.co.il
Important Japanese Clinical Trial in Recurrent Head & Neck Cancer
Alpha Tau Medical Ltd., the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has been notified by HekaBio K.K., its clinical trial partner in Japan, that recruitment has been completed in its open-label multi-center pivotal study evaluating the Alpha DaRT in Japanese patients with recurrent Head & Neck cancer after radiotherapy. - Click here if this is your press release! - eTurboNews | Trends | Travel News
Source: eturbonews.com
Alpha Tau Announces Completion of Enrollment of Japanese Pivotal Clinical Trial in Recurrent Head & Neck Cancer
/PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has...
Source: prnewswire.com
Alpha Tau Announces Completion of Enrollment of Japanese Pivotal Clinical Trial in Recurrent Head & Neck Cancer
/PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that it has...
Source: prnewswire.com